platoseedplatoseed
Genetic Medicine with Small Molecules
Serna Bio is developing small molecules to modulate RNA function, unlocking the potential to treat diseases driven by biology intractable by other modalities.
Serna Bio is an AI-enabled drug discovery company that designs small molecules targeting RNA to modulate translation and splicing. Their platform aims to expand druggable targets by shifting focus from proteins to RNA, using AI, synthetic biology, ML, and multiplexed screening.
The company designs small molecules that target RNA to modulate translation and splicing. It leverages AI to design unconstrained molecules for challenging-to-drug targets and employs massively multiplexed screening, enabling rational design of selective RNA-targeting compounds. The platform invites collaboration by offering a test drive on challenging targets.
Who it’s for: Biotech/health companies and pharmaceutical/biotech researchers seeking RNA-targeted small molecule therapeutics and targets with high unmet medical need
Hiring/traction information not provided; mentions collaboration and test-drive invitations, indicating outreach activity
Currently working on drugging RNA with small molecules. Previously built the ML team at Sensyne Health (UK PLC) // and worked at BenevolentAI. Love working at the intersection of biology / technology / business. Foodie at heart.
Formerly “Ladder Therapeutics” · why startups rename →
Combinations therapy by rational design
High quality mRNA for therapeutic application
